Cargando…

What Happens after Therapy? Quality of Life and Neurocognitive Functions of Children with Malignant Posterior Fossa Tumors after Adjuvant Therapy

PURPOSE: The health-related quality of life (HRQoL) is an important endpoint in modern clinical practice with improved survival of pediatric posterior fossa malignant brain tumors (PFMBTs). We evaluated the effect of environmental and psychosocial milieu on QoL and cognitive functioning (CF) of Indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeole, Ujwal, Hegde, Shantala, Gothwal, Mohit, Prabhuraj, AR, Somanna, Sampath, Thennarasu, K, Arimappamagan, Arivazhagan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613140/
https://www.ncbi.nlm.nih.gov/pubmed/34747802
http://dx.doi.org/10.4103/0028-3886.329599
_version_ 1783605448778186752
author Yeole, Ujwal
Hegde, Shantala
Gothwal, Mohit
Prabhuraj, AR
Somanna, Sampath
Thennarasu, K
Arimappamagan, Arivazhagan
author_facet Yeole, Ujwal
Hegde, Shantala
Gothwal, Mohit
Prabhuraj, AR
Somanna, Sampath
Thennarasu, K
Arimappamagan, Arivazhagan
author_sort Yeole, Ujwal
collection PubMed
description PURPOSE: The health-related quality of life (HRQoL) is an important endpoint in modern clinical practice with improved survival of pediatric posterior fossa malignant brain tumors (PFMBTs). We evaluated the effect of environmental and psychosocial milieu on QoL and cognitive functioning (CF) of Indian children with PFMBT. METHODS: In a cross-sectional study, 47 children <18 years of age with medulloblastoma or anaplastic ependymoma were evaluated ≥6 months after completion of adjuvant therapy. All clinical and socioeconomic details, educational status of child and family members, socioeconomic status, environmental factors affecting QoL were documented. Children underwent HRQoL evaluation using Pediatric quality of life Inventory (PedsQL) questionnaire and neuropsychological evaluation. RESULTS: The median age of the cohort at presentation was 7 years (1−18) and median duration of evaluation after adjuvant therapy was 16 months. In 47 families, 72.34% had low monthly income and 76.6% of mothers took formal education. QoL scores were above median values. Parents reported scores highlighted that Lansky performance score (P = 0.001) and maternal education (P = 0.043) significantly influenced the cognitive component of QoL. Twenty-seven children had below-average IQ. Young age at presentation (P = 0.020), maternal education (P = 0.032), high socioeconomic status (P = 0.001) influenced the IQ score. Even though the majority of children (57.44%) had below-average IQ, they had a score of more than 50 on the cognitive functioning scale. A total of 72.5% of the eligible children in our cohort went back to school following therapy, though often with a delay of one academic year. CONCLUSIONS: Overall cognitive functioning scores of these children are good, but they are not representative of actual neurocognitive tasks based performance or IQ scores. Children should remain under regular follow-up with a neurocognitive assessment and psychological counseling at regular intervals.
format Online
Article
Text
id pubmed-7613140
institution National Center for Biotechnology Information
language English
publishDate 2021
record_format MEDLINE/PubMed
spelling pubmed-76131402022-07-23 What Happens after Therapy? Quality of Life and Neurocognitive Functions of Children with Malignant Posterior Fossa Tumors after Adjuvant Therapy Yeole, Ujwal Hegde, Shantala Gothwal, Mohit Prabhuraj, AR Somanna, Sampath Thennarasu, K Arimappamagan, Arivazhagan Neurol India Article PURPOSE: The health-related quality of life (HRQoL) is an important endpoint in modern clinical practice with improved survival of pediatric posterior fossa malignant brain tumors (PFMBTs). We evaluated the effect of environmental and psychosocial milieu on QoL and cognitive functioning (CF) of Indian children with PFMBT. METHODS: In a cross-sectional study, 47 children <18 years of age with medulloblastoma or anaplastic ependymoma were evaluated ≥6 months after completion of adjuvant therapy. All clinical and socioeconomic details, educational status of child and family members, socioeconomic status, environmental factors affecting QoL were documented. Children underwent HRQoL evaluation using Pediatric quality of life Inventory (PedsQL) questionnaire and neuropsychological evaluation. RESULTS: The median age of the cohort at presentation was 7 years (1−18) and median duration of evaluation after adjuvant therapy was 16 months. In 47 families, 72.34% had low monthly income and 76.6% of mothers took formal education. QoL scores were above median values. Parents reported scores highlighted that Lansky performance score (P = 0.001) and maternal education (P = 0.043) significantly influenced the cognitive component of QoL. Twenty-seven children had below-average IQ. Young age at presentation (P = 0.020), maternal education (P = 0.032), high socioeconomic status (P = 0.001) influenced the IQ score. Even though the majority of children (57.44%) had below-average IQ, they had a score of more than 50 on the cognitive functioning scale. A total of 72.5% of the eligible children in our cohort went back to school following therapy, though often with a delay of one academic year. CONCLUSIONS: Overall cognitive functioning scores of these children are good, but they are not representative of actual neurocognitive tasks based performance or IQ scores. Children should remain under regular follow-up with a neurocognitive assessment and psychological counseling at regular intervals. 2021-09-01 /pmc/articles/PMC7613140/ /pubmed/34747802 http://dx.doi.org/10.4103/0028-3886.329599 Text en https://creativecommons.org/licenses/by/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non‑commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Article
Yeole, Ujwal
Hegde, Shantala
Gothwal, Mohit
Prabhuraj, AR
Somanna, Sampath
Thennarasu, K
Arimappamagan, Arivazhagan
What Happens after Therapy? Quality of Life and Neurocognitive Functions of Children with Malignant Posterior Fossa Tumors after Adjuvant Therapy
title What Happens after Therapy? Quality of Life and Neurocognitive Functions of Children with Malignant Posterior Fossa Tumors after Adjuvant Therapy
title_full What Happens after Therapy? Quality of Life and Neurocognitive Functions of Children with Malignant Posterior Fossa Tumors after Adjuvant Therapy
title_fullStr What Happens after Therapy? Quality of Life and Neurocognitive Functions of Children with Malignant Posterior Fossa Tumors after Adjuvant Therapy
title_full_unstemmed What Happens after Therapy? Quality of Life and Neurocognitive Functions of Children with Malignant Posterior Fossa Tumors after Adjuvant Therapy
title_short What Happens after Therapy? Quality of Life and Neurocognitive Functions of Children with Malignant Posterior Fossa Tumors after Adjuvant Therapy
title_sort what happens after therapy? quality of life and neurocognitive functions of children with malignant posterior fossa tumors after adjuvant therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613140/
https://www.ncbi.nlm.nih.gov/pubmed/34747802
http://dx.doi.org/10.4103/0028-3886.329599
work_keys_str_mv AT yeoleujwal whathappensaftertherapyqualityoflifeandneurocognitivefunctionsofchildrenwithmalignantposteriorfossatumorsafteradjuvanttherapy
AT hegdeshantala whathappensaftertherapyqualityoflifeandneurocognitivefunctionsofchildrenwithmalignantposteriorfossatumorsafteradjuvanttherapy
AT gothwalmohit whathappensaftertherapyqualityoflifeandneurocognitivefunctionsofchildrenwithmalignantposteriorfossatumorsafteradjuvanttherapy
AT prabhurajar whathappensaftertherapyqualityoflifeandneurocognitivefunctionsofchildrenwithmalignantposteriorfossatumorsafteradjuvanttherapy
AT somannasampath whathappensaftertherapyqualityoflifeandneurocognitivefunctionsofchildrenwithmalignantposteriorfossatumorsafteradjuvanttherapy
AT thennarasuk whathappensaftertherapyqualityoflifeandneurocognitivefunctionsofchildrenwithmalignantposteriorfossatumorsafteradjuvanttherapy
AT arimappamaganarivazhagan whathappensaftertherapyqualityoflifeandneurocognitivefunctionsofchildrenwithmalignantposteriorfossatumorsafteradjuvanttherapy